MMRGlobal, Inc. (fka MMRF)

[RUBY1100]

The Company plans on expanding its Boards of Advisors to include biotech financing and licensing expertise to help maximize the value of these assets. MMR understands that the samples and data may be of value in a possible successful reinterpretation of the pre-merger Favrille vaccine trials and that the IP may also unlock ways to create other "custom-made" cancer vaccines and be valuable in discovering additional opportunities in cancer research. The Company hopes to enter into additional licensing agreements with biopharmaceutical companies, academic institutions, research organizations and others regarding the use of its assets.